<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308528</url>
  </required_header>
  <id_info>
    <org_study_id>CRT062</org_study_id>
    <nct_id>NCT01308528</nct_id>
  </id_info>
  <brief_title>Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery</brief_title>
  <official_title>A Non-Inferiority Study of Enoxaparin Cristalia in Relation With Enoxaparin Sanofi-Aventis for Prophylaxis Against Venous Thromboembolism in Patients With High-Risk to Develop Thromboembolic Disease Undergoing Geral Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cristália Produtos Químicos Farmacêuticos Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and security and efficacy of sodium
      enoxaparin Cristália Produtos Químicos Farmaceuticos Ltda - Endocris with Clexane
      (Sanofi-Aventis) to prevent Venous Thromboembolism in Patients With High-Risk to Develop
      Thromboembolic Disease Undergoing Geral Abdominal Surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a requirement of Anvisa to add a new indication for off-label drug
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Sodium enoxaparin to demonstrate non-inferiority</measure>
    <time_frame>10 Days</time_frame>
    <description>Evaluation of Prophylactic use of Sodium enoxaparin to demonstrate non-inferiority for Venous Thromboembolism in High-Risk Surgery in Abdominal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of sodium enoxaparine</measure>
    <time_frame>10 days</time_frame>
    <description>comparision between Endocris (sodium enoxaparin - Cristalia Prod. Quim. Farm.) versus Clexane (sodium enoxaparine - Sanofi-Aventis) in High-Risk Abdominal Surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of venous thromboembolism and pulmonar embolism</measure>
    <time_frame>10 days</time_frame>
    <description>Compare the incidence of venous thromboembolism and pulmonar embolism between 2 groups after 30 days of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Sodium enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocris - 40 mg/0,4mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium enoxaparin Clexane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clexane - 40 mg/ 0,4mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium enoxaparin</intervention_name>
    <description>40 mg/mL</description>
    <arm_group_label>Sodium enoxaparin</arm_group_label>
    <other_name>Endocris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Enoxaparin clexane</intervention_name>
    <description>clexane 40 mg/ 0,4 mL</description>
    <arm_group_label>sodium enoxaparin Clexane</arm_group_label>
    <other_name>clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged above 18 years undergoing abdominal surgery with general high risk
             for developing venous thromboembolism;

          -  Who have provided their consent by signing the consent form.

        Exclusion Criteria:

          -  Clinical evidence of Venous thromboembolism (VTE) in the selection;

          -  treatment requirement with anticoagulant Low Molecular Weight Heparin, Unfracted
             Heparin, oral anticoagulant

          -  suspicion or history of coagulumpathia

          -  Heparin, enoxaparin allergy or hypersensitiviy known to heparin, enoxaparin, but not
             restrict to thrombocytopenia and/or induce thombose by heparin ou enoxaparin
             (thrombocytopenia induce by heparin [TIH], thrombocytopenia associate with heparin
             [TAH] or thrombotic thrombocytopenia syndrome induce by heparin [STTIH]

          -  Active bleeding that can be increased by enoxaparin.

          -  Previous history of known intracranial hemorrhage

          -  Artery-venous malformation or a suspicion or known cerebral aneurism

          -  Spinal, Epidural ou lumbar puncture analgesia in the last 24 hours previous of the
             first dose of the administration of the enoxaparin.

          -  erosive diseases of the digestive tract especially gastroduodenal

          -  Uncontrolled hypertension (systolic blood pressure [BP]&gt; 180mmHg or diastolic BP&gt; 100
             mm Hg) at randomization or clinical hypertensive urgency;

          -  bacterial endocarditis

          -  heart valve prosthesis

          -  characterized by severe renal insufficiency creatinine clearance &lt;30 ml / min

          -  Intra-arterial thrombolic therapy

          -  Thrombolic therapy within 24 hours.

          -  Low Molecular Weight Heparin or Unfraction Heparin treatment with prophylactic dose
             over 48 hours before surgery or oral anticoagulant within 5 days before surgery

          -  disturbance of consciousness and coma

          -  Less than 6 months of expectative time life

          -  Chemical dependency

          -  Patient with anesthetic risk ASA III or ASA IV

          -  morbid obesity with Body Mass Index ≥ 40

          -  Chronic use of corticosteroids

          -  History of allergy to Unfraction Heparin, Low molecular weight heparin or pork
             products.

          -  History of severe allergic episode, systemic anaphylaxis, or major urticarial disease
             Steven-Johnson

          -  Participation in another clinical study within 12 months prior to inclusion

          -  Potentially fertile woman without β-HCG negative harvested until 48 hours before
             operation or not using acceptable contraception for participation in this study

          -  Changes the security checks up to 48 h before randomization:

               -  Hemoglobin &lt;10 mg / dL;

               -  ALT or AST ≥ 2.5 times ULN;

               -  Platelet count &lt;100.000/mL;

               -  INR ≥ 1.5;

          -  Any condition which in the opinion of the investigator, could lead to increased risk
             for the patient or who makes it inappropriate for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilson R de Araujo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional da Asa Norte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Regional da Asa Norte</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huning Instituto de Oftalmologia e Pesquisa HIOP/HRPC</name>
      <address>
        <city>Canoas</city>
        <state>Rio Grande do Sul</state>
        <zip>92425-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação de Desenvolvimento da Unicamp - FUNCAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas de Riberião Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Mario Covas</name>
      <address>
        <city>Santo Andre</city>
        <state>São Paulo</state>
        <zip>09190615</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Multidisciplinar de Estudos Clínicos</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <state>São Paulo</state>
        <zip>09780000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São Jósé do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous Thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

